Please turn JavaScript on
header-image

Pharmaceutical Business review

Want to stay in touch with the latest updates from Pharmaceutical Business review? That's easy! Just subscribe clicking the Follow button below, choose topics or keywords for filtering if you want to, and we send the news to your inbox, to your phone via push notifications or we put them on your personal page here on follow.it.

Reading your RSS feed has never been easier!

Website title: Pharmaceutical Business review

Is this your feed? Claim it!

Publisher:  Unclaimed!
Message frequency:  1.33 / day

Message History

As part of the agreement, Idorsia will receive an upfront payment and retain marketing authorisations in each country.

Following local regulatory approval, the company will supply the finished product to Pharmalink at a pre-determined price. Pharmalink will handle sales, promotion, and distribution in the designated markets.

Quviviq is a dual orexin receptor ant...


Read full story

The approval marks the first authorised treatment for cerebral folate deficiency, a rare genetic neurological disorder affecting brain folate transport.

It followed a systematic review of published literature, including case reports with patient-level data and mechanistic studies.

CFD leads to seizures, movement disorders, developmental delays, and neurological ...


Read full story

This marks the first domestic anti-PD-1 monoclonal antibody in a subcutaneous formulation to reach the marketing application stage.

JS001sc is independently developed by Junshi Biosciences as a subcutaneous option based on the already marketed toripalimab injection.

The NDAs cover all approved indications of toripalimab in Mainland China.

The main support...


Read full story

The collaboration will integrate NewcelX’s NCEL-101 with Eledon’s investigational anti-cluster of differentiation 40 ligand (anti-CD40L) monoclonal antibody, tegoprubart (AT-1501), to support durable, immune-protected islet replacement and develop a possible functional cure for T1D.

Tegoprubart is developed to regulate immune activation pathways critical to T-cell–medi...


Read full story

Ecnoglutide is a cyclic adenosine monophosphate (cAMP)-biased glucagon-like peptide-1 (GLP-1) receptor agonist intended for chronic weight management in Chinese adults with obesity or who are overweight.

It is distinguished by its selective activation of the cAMP signalling pathway, reducing β-arrestin recruitment. This mechanism enables potent and sustained weight los...


Read full story